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Background: Cancer pain severely limits function and significantly reduces quality of life. Subtypes of sensory
neurons involved in cancer pain and proliferation are not clear.
Methods: We produced a cancer model by inoculating human oral squamous cell carcinoma (SCC) cells into the
hind paw of athymic mice. We quantified mechanical and thermal nociception using the paw withdrawal assays.
Neurotoxins isolectin B4-saporin (IB4-SAP), or capsaicin was injected intrathecally to selectively ablate IB4(+) neurons
or TRPV1(+) neurons, respectively. JNJ-17203212, a TRPV1 antagonist, was also injected intrathecally. TRPV1 protein
expression in the spinal cord was quantified with western blot. Paw volume was measured by a plethysmometer
and was used as an index for tumor size. Ki-67 immunostaining in mouse paw sections was performed to evaluate
cancer proliferation in situ.
Results: We showed that mice with SCC exhibited both mechanical and thermal hypersensitivity. Selective ablation
of IB4(+) neurons by IB4-SAP decreased mechanical allodynia in mice with SCC. Selective ablation of TRPV1(+)
neurons by intrathecal capsaicin injection, or TRPV1 antagonism by JNJ-17203212 in the IB4-SAP treated mice
completely reversed SCC-induced thermal hyperalgesia, without affecting mechanical allodynia. Furthermore, TRPV1
protein expression was increased in the spinal cord of SCC mice compared to normal mice. Neither removal of
IB4(+) or TRPV1(+) neurons affected SCC proliferation.
Conclusions: We show in a mouse model that IB4(+) neurons play an important role in cancer-induced mechanical
allodynia, while TRPV1 mediates cancer-induced thermal hyperalgesia. Characterization of the sensory fiber subtypes
responsible for cancer pain could lead to the development of targeted therapeutics.
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Cancer patients in pain suffer with a poor quality of life.
Approximately 75% to 90% of patients with advanced
cancer have pain that is particularly difficult to treat as
there is no effective analgesic available in treating in-
tractable cancer pain [1,2].
One strategic approach to cancer pain drug develop-
ment is targeted therapy against subtypes of nociceptors
that control specific sensory modalities. C-nociceptors, are
a heterogeneous population of neurons that are broadly* Correspondence: bls322@nyu.edu
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unless otherwise stated.divided into two subclasses. The peptidergic class does not
bind isolectin B4 (IB4), but expresses TRPV1, nerve
growth factor (NGF) receptor TrkA, and neuropeptides
such as calcitonin gene-related peptide (CGRP) and sub-
stance P (SP) [3,4]. The second subtype is nonpeptidergic
neurons, which binds IB4, expresses glial cell-derived
neurotrophic factor (GDNF) receptors and P2X3 recep-
tors, and has poor expression of SP and CGRP [5-8]. In
the spinal cord, IB4(+) neurons terminate predominantly
in inner lamina II whereas IB4(−) neurons terminate in
lamina I and outer lamina (II) [3,9]. The distinct neuro-
chemical and anatomical characteristics of the two subsets
lead some researchers to hypothesize that they have dif-
ferent functional properties in conveying nociceptiveThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that nonpeptidergic IB4(+) neurons and the peptidergic
TRPV1(+) neurons represent two parallel neuronal
pathways that selectively control mechanical and ther-
mal pain, respectively [10,12]. However, many other
studies did not find complete segregation between the
IB4(+) and TRPV1(+) neurons in mechanical vs. ther-
mal pain [15-18]. Some authors also hypothesized that
the two neuronal populations serve different functions
in pathological pain conditions with IB4(+) neurons
specifically contributing to neuropathic pain while
the TRPV1(+) neurons contribute to inflammatory
pain [19,20].
The differential involvement of IB4(+) and TRPV1(+)
neurons in cancer pain has not been well-characterized.
Our previous studies have demonstrated that the SCC
microenvironment contains high levels of NGF, which
mediates both mechanical and thermal nociception in
mouse models of SCC [21,22]. NGF is known to upre-
gulate and sensitize TRPV1 [23-26]. Indeed, TRPV1 ex-
pression is upregulated in neurons of mouse and rat
models of cancer [18,27,28]. TRPV1 also has been
shown to mediate both mechanical and thermal nocicep-
tion in a rat model of SCC [28]. In our mouse SCC
supernatant model (i.e. injection of SCC supernatant
into the hind paw of a naïve animal), mechanical allody-
nia is mediated by IB4(+) and NGF-responding neurons,
whereas thermal hyperalgesia is mediated exclusively by
NGF-responding neurons [22]. While the supernatant
model is useful for studying the effect of secretory prod-
uct from cancer cells on putative nociceptors, the effect
of supernatant is short-lasting and does not fully mimic
the cancer microenvironment. The specific roles of
IB4(+) and TRPV1(+) neurons in the cancer microenvir-
onment and their contribution to cancer pain need to be
determined.
In addition to their role in cancer pain, neurons could
also promote cancer progression [29,30]. Perineural inva-
sion, a process by which cancer cells invade and proliferate
within the nerve, is seen frequently in oral SCC [31-33].
Neurotransmitters released by the autonomic nervous sys-
tem, modulate proliferation, apoptosis, angiogenesis, and
metastasis [29]. Both surgical and chemical sympathec-
tomy can suppress tumor growth and invasiveness [34,35].
A recent study shows that SP(+) neurons promote cancer
proliferation and migration [36], suggesting that sensory
neurons could also contribute to the process of cancer
development.
Based on the above studies, we hypothesize that non-
peptidergic IB4(+) and peptidergic TRPV1(+) neurons
play differential roles in cancer pain and proliferation.
To test this hypothesis, we employ specific neurotoxins
to ablate, and pharmacological agents to selectively
antagonize, IB4(+) and TRPV1(+) neurons.Methods
Cell culture
The human oral SCC cell line, HSC-3 (ATCC, Manassas,
VA) was cultivated in Dulbecco’s Modification of Eagle’s
Medium (DMEM) with 4.5 g/L glucose, l-glutamine and
sodium pyruvate, supplemented with 10% fetal bovine
serum, 25 μg/mL fungizone, 100 μg/mL streptomycin
sulfate, and 100 U/mL penicillin G.
Experimental animals
34 female athymic, immunocompromised BALB/c mice
(6–8 weeks old, Charles River Laboratories, Hollister, CA)
were used in this study. Mice were exposed to a 12 hour
light–dark cycle and kept in a temperature-controlled
room with food and water ad libitum. All procedures were
approved by the New York University Institutional Animal
Care and Use Committee.
Intrathecal administration of drugs
Intrathecal injection of either IB4-SAP or capsaicin de-
stroys central terminals of IB4(+) and TRPV1(+) neu-
rons in the spinal cord and eventually kills the cell
bodies of these two populations in the DRGs as pre-
viously reported [10,22,37-40]. We observed more than
50% reduction in IB4 immunopositivity in the spinal
cord 2 weeks after IB4-SAP treatment [22]. All mice re-
ceived intrathecal injection of drugs while anesthetized
with 2.5% isoflurane. Drugs were delivered into the sub-
arachnoid space between the L4 and L5 vertebrae in the
spinal cord via a 10 μl Hamilton syringe. 1.53 mM IB4-
saporin (IB4-SAP, 53% saporin/mole IB4) or 0.81 mM
saporin (SAP, Advanced Targeting Systems, San Diego,
CA) was diluted with PBS to a total volume of 8 μl, and
were injected 2 weeks before SCC cell inoculation; as
SAP has no method of cell entry on its own and does
not change thermal or mechanical behaviours compared
to naive mice [22], it was used as a control. Capsaicin
(4 mM, Sigma Aldrich, St. Louis, MO), or vehicle (10%
ethanol, 10% Tween 80, 80% saline) at a volume of 8.0 μl
was injected 3 weeks post SCC inoculation (day 19). The
TRPV1 antagonist JNJ-17203212 (30 μM in 8 μl 5%
DMSO and 95% PBS, Sigma Aldrich, St. Louis, MO), or
vehicle was injected intrathecally at week 5 after SCC
inoculation.
Mouse cancer model
A paw SCC mouse model was used because paw with-
drawal is the gold standard for quantifying mechanical
and thermal behaviors, and because of technical chal-
lenges with the behavioral measurement and tumor size
monitoring in the oral region [21]. After recording base-
line behavior measurements, mice were injected with
106 HSC-3 cells in a 50 μl vehicle consisting of a mixture
of DMEM and Matrigel™ (Becton Dickinson & Co.,
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hind paw.
Paw volume measurement
Paw volume measurement was performed with a plethysm-
ometer (IITC Life Sciences, Woodland Hills, CA) and
taken as an index for tumor growth. Triplicate measure-
ments were taken for each time point.
Behavioral testing
Mechanical allodynia was quantified using an electronic
von Frey anesthesiometer (IITC Life Sciences, Woodland
Hills, CA). The withdrawal threshold was defined as the
force (g) sufficient to elicit a withdrawal response. Six
measurements were taken for each animal and the mean
was used as threshold for each animal at each time
point. Thermal hyperalgesia was measured using a paw
thermal stimulator (IITC Life Sciences, Woodland Hills,
CA). Mice were placed in a plastic chamber on a heated
glass surface (25ºC). A radiant heat source was focused
on the hind paw and latency to withdraw was measured
as the average of 6 trials per animal taken ≥ 5 minutes
apart. The cut-off latency was set at 20 seconds to avoid
tissue damage. Behavioral tests were performed at
2 weeks following IB4-SAP injection right before SCC
inoculation (baseline), at post inoculation week 2 (day
11) and week 4 (day 25). At post inoculation week 5
(day 32), the behavioral measurement was taken 30 min
after drug administration. The observer was blinded to
treatment groups in all behavioral experiments. The
mean of mechanical thresholds or thermal latency for
each group of animals was compared at each individual
time point. No group differences were found at baseline
for both mechanical and thermal assays.
Euthanasia and tissue processing
Mice were euthanized with isoflurane and perfused
transcardially with 0.1 M phosphate buffer saline (PBS)
at week 5 following SCC inoculation. The lumbar sec-
tion of the spinal cord was dissected, snap-frozen in li-
quid nitrogen and stored at −80ºC. Hind paws were
removed, post-fixed in 4% formaldehyde, and cryopro-
tected in sucrose gradient (20%-50%) at 4ºC. Serial fro-
zen paw sections (20 μm) were cut with a cryostat and
thaw-mounted on gelatin-coated slides for processing.
Western blotting
The spinal cord was lysed in ice-cold RIPA buffer with a
protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO).
Tissues were homogenized using a tissue homogenizer.
Spinal cord samples were loaded into the 10% polyacryl-
amide gels and then were electrotransferred onto a nitro-
cellulose membrane. The membranes were blocked with
10% non-fat dry milk in PBS with 0.3% Tween for 1 hourand then incubated overnight at 4°C with rabbit anti-
TRPV1 antibody (1:500; Alomone Labs, Jerusalem, Israel),
or GAPDH antibody (1:5000; Sigma Aldrich, St. Louis,
MO) diluted in PBS. The membrane was then incubated
in horseradish peroxidase-conjugated anti-rabbit IgG
(1:5000; Santa Cruz Biotechnology, Dallas, TX) for 2 hours
at room temperature. The antigen–antibody complexes
were visualized using an enhanced chemiluminescence
detection reagent (Bio-Rad Laboratories, Hercules, CA).
Bands were scanned using a densitometer (GS-700; Bio-
Rad Laboratories, Hercules, CA), and quantification was
performed using NIH Image J software.
Ki-67 labeling
Paw sections were stained for Ki-67 (rabbit anti-Ki67,
1:500; Abcam, Cambridge, MA), a nuclear protein emplo-
yed to quantify proliferation. After incubation in the pri-
mary antibody, sections were rinsed in PBS three times for
10 min each, and then incubated in the Texas Red goat
anti-rabbit secondary antibody (1:700; Jackson ImmunoR-
esearch Laboratories, West Grove, PA) for 1 hour at room
temperature. Image analysis was performed using NIH
Image J software. The area of staining was outlined and
pixel density within the selected area was then measured
and divided by the total area. Data were collected from 5
randomly selected sections from a minimum of 5 animals
per treatment group.
Statistical analysis
The statistics software SigmaPlot for Windows (version
11.0) was used to perform the statistical analysis. One-
way ANOVA with a Tukey Multiple Comparisons post-
hoc test was used to compare the experimental groups.
Significance level was set at p < 0.05. Results were pre-
sented as mean ± standard error (SE).
Results
SCC induced both mechanical allodynia and thermal
hyperalgesia
2 weeks following intrathecal injection, IB4-SAP treated
mice exhibited similar baseline mechanical or thermal be-
haviour compared to SAP treated mice (Figure 1A). After
SCC inoculation, both SAP and IB4-SAP treated mice ex-
hibited decreased paw withdrawal thresholds to mechanical
stimulation compared to their pre-inoculation thresholds
throughout the four week observation period (Figure 1A).
Mice with SCC also demonstrated decreased thermal la-
tency post-inoculation compared to their pre-inoculation
baseline (Figure 1B).
IB4-SAP treatment reduced mechanical allodynia, but
increased thermal hyperalgesia
While both vehicle control mice and IB4-SAP treated mice
developed mechanical allodynia following SCC inoculation
Figure 1 Nociceptive behavior in IB4-SAP and SAP treated SCC mice. A. Mechanical thresholds were decreased from baseline following
SCC inoculation in both treatment groups (P < 0.001 for baseline vs. week 2 and week 4 in the IB4-SAP and SAP groups). IB4-SAP (N = 8) and
SAP (N = 8) treated mice had similar mechanical thresholds at baseline and at post inoculation week 2. However, IB4-SAP significantly reduced
SCC-induced mechanical allodynia compared to SAP treated mice at week 4 post inoculation (*, P < 0.05). While no difference in mechanical
thresholds was found in IB4-SAP group between week 2 and week 4, mechanical thresholds were significantly reduced in SAP mice from week
2 to week 4 (#, P < 0.001). B. Thermal latency was decreased from baseline following SCC inoculation (P < 0.001 for baseline vs. week 2 and week
4 in the IB4-SAP and SAP groups). IB4-SAP and SAP treated mice had similar thermal latency at baseline and at week 2 post inoculation.
IB4-SAP treatment significantly increased thermal hyperalgesia compared to SAP treated mice at week 4 post inoculation (*, P < 0.05).
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treatment led to significant attenuation of mechanical al-
lodynia at week 4, but not at week 2, compared to mice
(Figure 1A). However, IB4-SAP treatment led to increased
thermal hyperalgesia at week 4 post SCC inoculation,
compared to the control SAP-treated group (Figure 1B).SCC induced thermal hyperalgesia was mediated by TRPV1
To determine whether TRPV1 contributed to thermal
hyperalgesia induced by SCC inoculation and IB4-SAP
treatment, we quantified nociceptive behavior after in-
trathecal injection of capsaicin into IB4-SAP pre-treated
mice during post SCC inoculation week 3. Capsaicin, a
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neurons [10], significantly reduced SCC-induced thermal
hyperalgesia without affecting mechanical allodynia, at
post SCC inoculation week 4 and 5 (i.e., one week and
two weeks after capsaicin treatment) (Figure 2). Similarly,
TRPV1 antagonism by intrathecal JNJ-17203212 at week 5
in IB4-SAP treated mice with SCC also reversed thermal
hyperalgesia with no effect on mechanical allodynia
(Figure 2). To determine whether the thermal hyperalgesicFigure 2 Nociceptive behavior in IB4-SAP treated SCC mice injected w
were used in each group. All mice were treated with IB4-SAP 2 weeks befo
inoculation. JNJ-17203212 was injected intrathecally 30 min before the beh
thresholds was found among capsaicin, JNJ-17203212, or vehicle injected S
inoculation). All animals in the capsaicin, JNJ-17203212, and vehicle injecte
week 4, and week 5 relative to baseline (P < 0.001 in all measurements). B.
4 and 5, one and two weeks after capsaicin injection, respectively (*, P < 0.0
capsaicin vs. vehicle at week 5). JNJ-17203212 injection also reversed thermeffect was accompanied by increased expression of TRPV1
we measured TPRV1 protein levels in the spinal cord.
Western blotting showed that TRPV1 expression was in-
creased in the spinal cord of mice with SCC compared to
untreated, normal (naïve) mice (Figure 3). TRPV1 protein
expression was increased in mice with SCC that were
treated with IB4-SAP versus those that were treated with
control SAP, although this trend was not statistically sig-
nificant (data not shown). The thermal hyperalgesic effectith capsaicin and the TRPV1 antagonist (JNJ-17203212). Six mice
re SCC inoculation. Capsaicin was injected intrathecally at week 3 post
avior measurement at week 5. A. No difference in mechanical
CC mice throughout the observation time (5 weeks after SCC
d groups had reduced mechanical thresholds from baseline at week 2,
Capsaicin injection significantly reversed thermal hyperalgesia at weeks
5; capsaicin vs. vehicle or JNJ-17203212 at week 4; **, P < 0.01
al hyperalgesia at week 5 (**, P < 0.01, JNJ-17203212 vs. vehicle).
Figure 3 Spinal TRPV1 protein was increased in cancer mice.
TRPV1 protein expression was increased in the spinal cords of SCC
mice (N = 6) at week 5 following SCC inoculation compared to naive
mice (N = 5). Western blots were performed to isolate and measure
TRPV1; GAPDH was used as the reference protein. **, P < 0.01.
Figure 4 Paw volume was not different across SCC mice
treatment groups. A. Paw volume was not different between SAP
and IB4-SAP treated SCC mice (N = 6 in each group) at baseline or
at week 4. B. Paw volume was not different among capsaicin,
JNJ-17203212, or vehicle injected SCC mice at baseline or at week
5. *, P < 0.05; **, P < 0.01.
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IB4-SAP treatment, was therefore mediated by TRPV1.
IB4(+) and TRPV1(+) neurons did not affect SCC
proliferation
We found that selective ablation of IB4(+) neurons with
IB4-SAP treatment only affected SCC-induced nocicep-
tion (i.e. decreased mechanical allodynia and increased
thermal hyperalgesia compared to control), but not SCC
proliferation. Paw volume measurements were not signifi-
cantly different between mice with SCC treated with IB4-
SAP and those treated with control SAP (Figure 4A); paw
volume measurements were comparable to our previous
report in mice inoculated with SCC [21]. Ablation of
TRPV1(+) neurons also had no further effect on paw
tumor volume in mice with SCC treated with IB4-SAP
(Figure 4B). In histological sections of paw SCC, both IB4-
SAP and SAP-treated mice had similar proportions of
Ki-67-positive cells among DAPI-positive cells (Figure 5).
Discussion
The cancer microenvironment is densely innervated; how-
ever, the specific sensory fiber types responsible for cancer
pain are not known. Behavioral characterization of the
peripheral neuronal subtypes responsible for cancer pain
would lend itself to targeted pharmacologic management
of cancer pain. Here, using a cancer pain mouse model we
selectively ablated two separate populations of putative
nociceptors innervating the cancer microenvironment and
observed distinct behavioral changes. Selective ablation
of each of these fiber types did not impact cancer
proliferation.
Our data suggest that IB4(+) and TRPV1(+) neurons
have functionally distinct roles in cancer pain, at least in
the level of mouse DRG and spinal cord, where few IB4(+)
neurons overlap with TRPV1 [10,41], in contrast to rat
DRG [14,42]. Scherrer et al., [10] show that IB4(+) and
TRPV1(+) neurons exclusively express delta-opioid recep-
tors (DOR) and mu-opioid receptors (MOR), respectively.
In these mice intrathecal DOR agonists reduce mechan-
ical allodynia, while MOR agonists reduce thermalhyperalgesia [10]. Likewise, genetic ablation of IB4(+)
neurons reduces mechanical hypersensitivity, but not
thermal hypersensitivity. On the other hand, phar-
maxcological ablation of TRPV1(+) neurons selectively
abolishes thermal hypersensitivity without affecting
mechanical hypersensitivity [12]. It should be noted,
however, that there are studies suggesting that MOR
and DOR are colocalized and do not mediate distinct
pain behaviors [17,18,43]. In rats, IB4-SAP treatment af-
fects both mechanical and thermal sensitivity [37,44],
probably due to expression of TRPV1 on IB4(+) neu-
rons in rats [14,42]. TRPV1 also has been shown to
mediate both mechanical and thermal nociception in
cancer models of rats and dogs [28,45,46]. Such differ-
ences in IB4(+) and TRPV1(+) function may due to dif-
ferences in species, experimental approaches, disease
models, and behavioral assays. Therefore, additional
Figure 5 Ki-67 and 4′,6-diamidino-2-phenylindole (DAPI)
immunostaining in paw sections processed at weeks 5
following SCC inoculation. A. An example of Ki-67 and DAPI
staining in the paw section of IB4-SAP treated SCC mouse. B. An
example of Ki-67 and DAPI staining in the paw section of SAP
treated SCC mouse. C. Quantification of Ki-67-positive cells in total
DAPI-positive cells showed no difference between IB4-SAP and SAP
treated mice. Horizontal scale bar, 100 μm.
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restricted to our specific cancer model and strain of
mice. Moreover, we used athymic mice which lack cell
mediated immunity. It is unknown whether nociceptive
fibers differ in either function or neurochemical expres-
sion in athymic mice compared to normal mice.Nevertheless, the role of IB4(+) neurons in mechanical
hypersensitivity is demonstrated by a large body of evidence
[5,22,39,44,47-49]. Using intrasciatic IB4-SAP injection,
IB4(+) neurons have been shown to mediate mechanical
sensitivity in normal conditions and after injury [37,44].
In contrast to peripheral IB4-SAP treatment, intrathecal
IB4-SAP treatment did not seem to cause behaviour
changes at the basal conditions in our model. Basal mech-
anical hypoalgesia has not been shown in other studies
using intrathecal IB4-SAP treatment in rats [39,40,47,48].
However, there is a clear evidence that IB4-SAP treatment
reduces mechanical allodynia in animal models of neuro-
pathic pain [39,44,47,48]. The role of IB4(+) neurons in
cancer induced mechanical allodynia is just emerging.
Mechanical allodynia is a cardinal, and often the initial,
symptom in cancer patients [50-52]. Using a cancer pain
mouse model that is produced by injecting SCC super-
natant into the hind paw, we previously showed that
extracellular secretions from the cancer, not growth of the
cancer, directly produced mechanical allodynia [22]. SCC
secretes neurturin, a neurotrophic factor of the GDNF
family, which could activate and sensitize IB4(+) neurons
to mechanical stimulation [22]. Mechanical transducers
such as TRPA1 and P2X3, which are expressed on IB4(+)
neurons, could also contribute to IB4(+) mediated mech-
anical pain [6,41,53,54].
Ablation of IB4(+) neurons only partially reduced
SCC-induced mechanical allodynia. This partial antino-
ciceptive effect might be a result of incomplete destruc-
tion of IB4(+) neurons by IB4-SAP treatment at the
time of the nociceptive behavioral measurements. Previ-
ous studies have reported that 55-100% of IB4(+) neurons
are abolished by 21 days following IB4-SAP treatment
[37,44,53,55]. Using the same approach as we did here, a
more than 50% decrease in IB4 immunointensity was ob-
served 2 weeks following IB4-SAP treatment in C57BL/6
mice with no cancer [22]. In our study, cancer-induced
mechanical allodynia was partially reduced, but not com-
pletely abolished, on day 46 post IB4-SAP treatment; it is
likely that IB4(+) fiber destruction is not complete in our
cancer model. Indeed, our preliminary experiments using
immunofluorescent staining showed a 68% reduction of
IB4(+) neurons in the DRGs of IB4-SAP treated mice
compared to SAP-treated mice; similarly, a partial reduc-
tion of IB4(+) fibers in the spinal cord of IB4-SAP treated
mice is also observed (data not shown). In addition, a
separate subtype of neurons (i.e. IB4(−)/NGF-responsive
neurons) could contribute to the residual mechanical allo-
dynia observed in our IB4-SAP treated cancer mice. We
have previously showed that IB4(−)/NGF-responsive neu-
rons mediated SCC supernatant induced mechanical allo-
dynia [21,22]. This IB4(−)/NGF fiber population either
does not express TRPV1 or TRPV1 does not mediate
mechanical stimulation in these fibers, as we did not
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mechanical hypersensitivity.
The observed thermal hyperalgesia in mice with SCC
could result from SCC-mediated secretion of algogenic
agents such as NGF, ATP, and endothelin-1, which are
known to cause thermal hyperalgesia [21,56], possibly
through the TRPV1 receptor [57-61]. TRPV1-dependent
thermal hyperalgesia is present in animal models of SCC
[22,27,28,61] and bone cancer [62,63]. TRPV1 anta-
gonism reduces cancer-induced thermal hyperalgesia in
these models [62]. We also demonstrated the role of
TRPV1 in SCC-induced thermal hyperalgesia in our
model. Unexpectedly, IB4-SAP treatment enhanced ther-
mal hyperalgesia in mice with SCC. This enhanced ther-
mal hyperalgesic effect was not present until four weeks
after IB4-SAP treatment, and was completely abolished
with TRPV1 antagonism. This enhanced thermal hyper-
algesia observed in IB4-SAP treated mice at post SCC
inoculation week 4 could result from compensatory
TRPV1(+) neuronal sprouting secondary to the loss of
IB4(+) neurons in the spinal cord. Evidence supporting
neuronal sprouting following IB4-SAP treatment has
been equivocal. In rats there is no increase in sprouting
of peptidergic IB4(−) neurons in dorsal root ganglion
(DRG) or spinal cord following ablation of nonpepti-
dergic IB4(+) neurons with IB4-SAP treatment during a
30-day observation period [64]. On the other hand, a
separate study in rats shows that IB4-SAP ablation of
IB4(+) neurons in the mental nerve results in significant
sprouting of parasympathetic fibers into the upper der-
mis at week 3 following IB4-SAP treatment [55].
Compensatory sprouting of nerve fibers might explain
why we did not observe an antiproliferative effect by abla-
tion of either IB4(+) or both IB4(+) and TRPV1(+) neu-
rons. Interaction between cancer cells and the nervous
system leads to a reciprocal proliferative effect [30]. Can-
cer cells, including prostate and pancreatic, can stimulate
neurite outgrowth [65]. The nervous system especially the
sympathetic nervous system contributes to cancer prolifer-
ation, migration, invasion and metastasis [29,34,35,66].
Our finding that pharmacologic ablation of IB4(+) and
TRPV1(+) subtypes did not lead to a decrease in proli-
feration could be due to compensatory sprouting of
autonomic or sensory neurons which maintains cancer
proliferation. It has to be noted, however, that capsaicin
or TRPV1 antagonists applied directly to oral SCC can
exert an anti-proliferative effect by a mechanism that is
independent of TRPV1 [67]. Another explanation for
our findings is that our chemical ablation methods (e.g.
IB4-SAP or capsaicin) only destroy central terminals of
DRG neurons but leaves peripheral terminals in the
vicinity of the tumor relatively intact and functional.
Therefore, the role of efferent neuronal activity in can-
cer proliferation remains inconclusive.Conclusions
Our study demonstrated distinct roles of nonpeptidergic
IB4(+) and peptidergic TRPV1(+) neurons in mediating
cancer-induced nociception. We determined that TRPV1(+)
neurons are involved exclusively in cancer-induced ther-
mal hyperalgesia, but not mechanical allodynia in our
mouse paw SCC model. Identification of subpopulation of
neurons mediating SCC-induced pain is of clinical import-
ance as mechanical pain is a primary symptom of oral
SCC patients. Drug therapy targeting specific nociceptors
could lead to more effective treatment of cancer-induced
mechanical pain.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YY designed the study and YY wrote the draft of the manuscript. SB
performed behaviour assessments for the animals. YY inoculated cancer cells,
performed drug injections, western blot, and immunostaining. DB and ST
quantified immunostaining images. CTV helped edit the manuscript. BLS
supervised the project and the writing of the paper. All authors contributed
to and have approved the final manuscript.
Acknowledgements
This work was funded by NIH/NIDCR R21 DE018561 and R01 DE19796.
Author details
1Bluestone Center for Clinical Research, New York University, New York, USA.
2Department of Oral and Maxillofacial Surgery, University of Michigan, Ann
Arbor, USA. 3Department of Oral Maxillofacial Surgery, New York University,
New York, USA. 4Department of Otolaryngology, Head and Neck Surgery,
New York University, New York, USA. 5Oral Oncology Center, Aracatuba
Dental School, University of Estadual Paulista, Aracatuba, San Paulo, Brazil.
Received: 8 November 2013 Accepted: 30 January 2014
Published: 13 February 2014
References
1. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S:
Symptoms during cancer pain treatment following WHO-guidelines: a
longitudinal follow-up study of symptom prevalence, severity and
etiology. Pain 2001, 93:247–257.
2. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine
ML, Clohisy DR, Mantyh PW: Neurochemical and cellular reorganization of
the spinal cord in a murine model of bone cancer pain. J Neurosci 1999,
19:10886–10897.
3. Molliver DC, Radeke MJ, Feinstein SC, Snider WD: Presence or absence of
TrkA protein distinguishes subsets of small sensory neurons with unique
cytochemical characteristics and dorsal horn projections. J Comp Neurol
1995, 361:404–416.
4. Price TJ, Flores CM: Critical evaluation of the colocalization between
calcitonin gene-related peptide, substance P, transient receptor potential
vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding
in primary afferent neurons of the rat and mouse. J Pain 2007, 8:263–272.
5. Albers KM, Woodbury CJ, Ritter AM, Davis BM, Koerber HR: Glial cell-line-
derived neurotrophic factor expression in skin alters the mechanical
sensitivity of cutaneous nociceptors. J Neurosci 2006, 26:2981–2990.
6. Bradbury EJ, Burnstock G, McMahon SB: The expression of P2X3
purinoreceptors in sensory neurons: effects of axotomy and glial-derived
neurotrophic factor. Mol Cell Neurosci 1998, 12:256–268.
7. Golden JP, Hoshi M, Nassar MA, Enomoto H, Wood JN, Milbrandt J,
Gereau RW, Johnson EM Jr, Jain S: RET signaling is required for survival
and normal function of nonpeptidergic nociceptors. J Neurosci 2010,
30:3983–3994.
8. Molliver DC, Wright DE, Leitner ML, Parsadanian AS, Doster K, Wen D, Yan Q,
Snider WD: IB4-binding DRG neurons switch from NGF to GDNF
dependence in early postnatal life. Neuron 1997, 19:849–861.
Ye et al. Behavioral and Brain Functions 2014, 10:5 Page 9 of 10
http://www.behavioralandbrainfunctions.com/content/10/1/59. Silverman JD, Kruger L: Selective neuronal glycoconjugate expression in
sensory and autonomic ganglia: relation of lectin reactivity to peptide
and enzyme markers. J Neurocytol 1990, 19:789–801.
10. Scherrer G, Imamachi N, Cao Y-Q, Contet C, Mennicken F, O’Donnell D,
Kieffer BL, Basbaum AI: Dissociation of the opioid receptor mechanisms
that control mechanical and heat pain. Cell 2009, 137:1148–1159.
11. Braz JM, Nassar MA, Wood JN, Basbaum AI: Parallel “pain” pathways arise
from subpopulations of primary afferent nociceptor. Neuron 2005,
47:787–793.
12. Cavanaugh DJ, Lee H, Lo L, Shields SD, Zylka MJ, Basbaum AI, Anderson DJ:
Distinct subsets of unmyelinated primary sensory fibers mediate
behavioral responses to noxious thermal and mechanical stimuli.
Proc Natl Acad Sci 2009, 106:9075–9080.
13. Dirajlal S, Pauers LE, Stucky CL: Differential response properties of IB(4)-
positive and -negative unmyelinated sensory neurons to protons and
capsaicin. J Neurophysiol 2003, 89:513–524.
14. Stucky CL, Lewin GR: Isolectin B(4)-positive and -negative nociceptors are
functionally distinct. J Neurosci 1999, 19:6497–6505.
15. Woodbury CJ, Zwick M, Wang S, Lawson JJ, Caterina MJ, Koltzenburg M,
Albers KM, Koerber HR, Davis BM: Nociceptors lacking TRPV1 and TRPV2
have normal heat responses. J Neurosci 2004, 24:6410–6415.
16. Lawson JJ, McIlwrath SL, Woodbury CJ, Davis BM, Koerber HR: TRPV1 unlike
TRPV2 is restricted to a subset of mechanically insensitive cutaneous
nociceptors responding to heat. J Pain 2008, 9:298–308.
17. Wang HB, Zhao B, Zhong YQ, Li KC, Li ZY, Wang Q, Lu YJ, Zhang ZN, He SQ,
Zheng HC, Wu SX, Hökfelt TG, Bao L, Zhang X: Coexpression of delta- and
mu-opioid receptors in nociceptive sensory neurons. Proc Natl Acad Sci U S A
2010, 107:13117–13122.
18. Beaudry H, Dubois D, Gendron L: Activation of spinal mu- and delta-opioid
receptors potently inhibits substance P release induced by peripheral
noxious stimuli. J Neurosci 2011, 31:13068–13077.
19. Snider WD, McMahon SB: Tackling pain at the source: new ideas about
nociceptors. Neuron 1998, 20:629–632.
20. Mantyh PW, Hunt SP: Hot peppers and pain. Neuron 1998, 21:644–645.
21. Ye Y, Dang D, Zhang J, Viet CT, Lam DK, Dolan JC, Gibbs JL, Schmidt BL:
Nerve growth factor links oral cancer progression, pain, and cachexia.
Mol Cancer Ther 2011, 10:1667–1676.
22. Ye Y, Dang D, Viet CT, Dolan JC, Schmidt BL: Analgesia targeting
IB4-positive neurons in cancer-induced mechanical hypersensitivity.
J Pain 2012, 13:524–531.
23. Amaya F, Shimosato G, Nagano M, Ueda M, Hashimoto S, Tanaka Y, Suzuki
H, Tanaka M: NGF and GDNF differentially regulate TRPV1 expression that
contributes to development of inflammatory thermal hyperalgesia.
Eur J Neurosci 2004, 20:2303–2310.
24. Jankowski MP, Koerber HR: Neurotrophic factors and nociceptor
sensitization. In Translational Pain Research: From Mouse to Man. Edited by
Kruger L, Light AR. Boca Raton, FL: Frontiers in Neuroscience; 2010.
25. Stein AT, Ufret-Vincenty CA, Hua L, Santana LF, Gordon SE: Phosphoinositide
3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to
the plasma membrane. J Gen Physiol 2006, 128:509–522.
26. Zhang X, Huang J, McNaughton PA: NGF rapidly increases membrane
expression of TRPV1 heat-gated ion channels. EMBO J 2005, 24:4211–4223.
27. Asai H, Ozaki N, Shinoda M, Nagamine K, Tohnai I, Ueda M, Sugiura Y: Heat and
mechanical hyperalgesia in mice model of cancer pain. Pain 2005, 117:19–29.
28. Shinoda M, Ogino A, Ozaki N, Urano H, Hironaka K, Yasui M, Sugiura Y:
Involvement of TRPV1 in nociceptive behavior in a rat model of cancer
pain. J Pain 2008, 9:687–699.
29. Schuller HM: Neurotransmission and cancer: implications for prevention
and therapy. Anticancer Drugs 2008, 19:655–671.
30. Mancino M, Ametller E, Gascon P, Almendro V: The neuronal influence on
tumor progression. Biochim Biophys Acta 1816, 2011:105–118.
31. Fagan JJ, Collins B, Barnes L, D’Amico F, Myers EN, Johnson JT: Perineural
invasion in squamous cell carcinoma of the head and neck. Arch
Otolaryngol Head Neck Surg 1998, 124:637–640.
32. Kolokythas A, Cox DP, Dekker N, Schmidt BL: Nerve growth factor (NGF)
and tyrosine kinase A (Trk A) receptor in oral squamous cell carcinoma:
is there an association with perineural invasion? J Oral Maxillofac Surg
2010, 68:1290–1295.
33. Rahima B, Shingaki S, Nagata M, Saito C: Prognostic significance of
perineural invasion in oral and oropharyngeal carcinoma. Oral Surg Oral
Med Oral Pathol Oral Radiol Endod 2004, 97:423–431.34. Raju B, Haug SR, Ibrahim SO, Heyeraas KJ: Sympathectomy decreases
size and invasiveness of tongue cancer in rats. Neuroscience 2007,
149:715–725.
35. Raju B, Hultstrom M, Haug SR, Ibrahim SO, Heyeraas KJ: Sympathectomy
suppresses tumor growth and alters gene-expression profiles in rat
tongue cancer. Eur J Oral Sci 2009, 117:351–361.
36. Feng F, Yang J, Tong L, Yuan S, Tian Y, Hong L, Wang W, Zhang H:
Substance P immunoreactive nerve fibres are related to gastric cancer
differentiation status and could promote proliferation and migration of
gastric cancer cells. Cell Biol Int 2011, 35:623–629.
37. Vulchanova L, Olson TH, Stone LS, Riedl MS, Elde R, Honda CN: Cytotoxic
targeting of isolectin IB4-binding sensory neurons. Neuroscience 2001,
108:143–155.
38. Nishiguchi J, Sasaki K, Seki S, Chancellor MB, Erickson KA, de Groat WC,
Kumon H, Yoshimura N: Effects of isolectin B4-conjugated saporin, a
targeting cytotoxin, on bladder overactivity induced by bladder
irritation. Eur J Neurosci 2004, 20:474–482.
39. Joseph EK, Chen X, Bogen O, Levine JD: Oxaliplatin acts on IB4-positive
nociceptors to induce an oxidative stress-dependent acute painful
peripheral neuropathy. J Pain 2008, 9:463–472.
40. Bogen O, Joseph EK, Chen X, Levine JD: GDNF hyperalgesia is mediated
by PLCgamma, MAPK/ERK, PI3K, CDK5 and Src family kinase signaling
and dependent on the IB4-binding protein versican. Eur J Neurosci 2008,
28:12–19.
41. Zwick M, Davis BM, Woodbury CJ, Burkett JN, Koerber HR, Simpson JF,
Albers KM: Glial cell line-derived neurotrophic factor is a survival factor
for isolectin B4-positive, but not vanilloid receptor 1-positive, neurons in
the mouse. J Neurosci 2002, 22:4057–4065.
42. Fang X, Djouhri L, McMullan S, Berry C, Waxman SG, Okuse K, Lawson SN:
Intense isolectin-B4 binding in rat dorsal root ganglion neurons
distinguishes C-fiber nociceptors with broad action potentials and high
Nav1.9 expression. J Neurosci 2006, 26:7281–7292.
43. Normandin A, Luccarini P, Molat JL, Gendron L, Dallel R: Spinal mu and
delta opioids inhibit both thermal and mechanical pain in rats. J Neurosci
2013, 33:11703–11714.
44. Tarpley JW, Kohler MG, Martin WJ: The behavioral and neuroanatomical
effects of IB4-saporin treatment in rat models of nociceptive and
neuropathic pain. Brain Res 2004, 1029:65–76.
45. Iadarola MJ, Mannes AJ: The vanilloid agonist resiniferatoxin for
interventional-based pain control. Curr Top Med Chem 2011, 11:2171–2179.
46. Brown DC, Iadarola MJ, Perkowski SZ, Erin H, Shofer F, Laszlo KJ, Olah Z,
Mannes AJ: Physiologic and antinociceptive effects of intrathecal
resiniferatoxin in a canine bone cancer model. Anesthesiology 2005,
103:1052–1059.
47. Joseph EK, Levine JD: Hyperalgesic priming is restricted to isolectin
B4-positive nociceptors. Neuroscience 2010, 169:431–435.
48. Joseph EK, Levine JD: Mu and delta opioid receptors on nociceptors
attenuate mechanical hyperalgesia in rat. Neuroscience 2010, 171:344–350.
49. Hucho TB, Dina OA, Levine JD: Epac mediates a cAMP-to-PKC signaling in
inflammatory pain: an isolectin B4(+) neuron-specific mechanism.
J Neurosci 2005, 25:6119–6126.
50. Connelly ST, Schmidt BL: Evaluation of pain in patients with oral
squamous cell carcinoma. J Pain 2004, 5:505–510.
51. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC,
van Kleef M, Patijn J: Prevalence of pain in patients with cancer: a
systematic review of the past 40 years. Ann Oncol 2007, 18:1437–1449.
52. Viet CT, Ye Y, Dang D, Lam DK, Achdjian S, Zhang J, Schmidt BL: Re-
expression of the methylated EDNRB gene in oral squamous cell
carcinoma attenuates cancer-induced pain. Pain 2011, 152:2323–2332.
53. Vulchanova L, Riedl MS, Shuster SJ, Stone LS, Hargreaves KM, Buell G,
Surprenant A, North RA, Elde R: P2X3 is expressed by DRG neurons that
terminate in inner lamina II. Eur J Neurosci 1998, 10:3470–3478.
54. Barabas ME, Kossyreva EA, Stucky CL: TRPA1 is functionally expressed
primarily by IB4-binding, non-peptidergic mouse and rat sensory
neurons. PLoS One 2012, 7:e47988.
55. Taylor AM, Osikowicz M, Ribeiro-da-Silva A: Consequences of the ablation
of nonpeptidergic afferents in an animal model of trigeminal
neuropathic pain. Pain 2012, 153:1311–1319.
56. Pickering V, Jay Gupta R, Quang P, Jordan RC, Schmidt BL: Effect of
peripheral endothelin-1 concentration on carcinoma-induced pain in
mice. Eur J Pain 2007, 12:293–300.
Ye et al. Behavioral and Brain Functions 2014, 10:5 Page 10 of 10
http://www.behavioralandbrainfunctions.com/content/10/1/557. Motta EM, Calixto JB, Rae GA: Mechanical hyperalgesia induced by
endothelin-1 in rats is mediated via phospholipase C, protein kinase C,
and MAP kinases. Exp Biol Med (Maywood) 2006, 231:1141–1145.
58. Huang J, Zhang X, McNaughton PA: Inflammatory pain: the cellular basis
of heat hyperalgesia. Curr Neuropharmacol 2006, 4:197–206.
59. Kawamata T, Ji W, Yamamoto J, Niiyama Y, Furuse S, Namiki A: Contribution
of transient receptor potential vanilloid subfamily 1 to endothelin-1-
induced thermal hyperalgesia. Neuroscience 2008, 154:1067–1076.
60. Moriyama T, Iida T, Kobayashi K, Higashi T, Fukuoka T, Tsumura H, Leon C,
Suzuki N, Inoue K, Gachet C, Noguchi K, Tominaga M: Possible involvement of
P2Y2 metabotropic receptors in ATP-induced transient receptor potential
vanilloid receptor 1-mediated thermal hypersensitivity. J Neurosci 2003,
23:6058–6062.
61. Nagamine K, Ozaki N, Shinoda M, Asai H, Nishiguchi H, Mitsudo K, Tohnai I,
Ueda M, Sugiura Y: Mechanical allodynia and thermal hyperalgesia
induced by experimental squamous cell carcinoma of the lower gingiva
in rats. J Pain 2006, 7:659–670.
62. Menendez L, Juarez L, Garcia E, Garcia-Suarez O, Hidalgo A, Baamonde A:
Analgesic effects of capsazepine and resiniferatoxin on bone cancer pain
in mice. Neurosci Lett 2006, 393:70–73.
63. Menendez L, Juarez L, Garcia V, Hidalgo A, Baamonde A: Involvement of
nitric oxide in the inhibition of bone cancer-induced hyperalgesia
through the activation of peripheral opioid receptors in mice.
Neuropharmacology 2007, 53:71–80.
64. Zinck NDT, Downie JW: IB4 afferent sprouting contributes to bladder
dysfunction in spinal rats. Exp Neurol 2008, 213:293–302.
65. Dai H, Li R, Wheeler T, Ozen M, Ittmann M, Anderson M, Wang Y, Rowley D,
Younes M, Ayala GE: Enhanced survival in perineural invasion of
pancreatic cancer: an in vitro approach. Hum Pathol 2007, 38:299–307.
66. Li ZJ, Cho CH: Neurotransmitters, more than meets the eye–
neurotransmitters and their perspectives in cancer development
and therapy. Eur J Pharmacol 2011, 667:17–22.
67. Gonzales CB, Kirma NB, De La Chapa JJ, Chen R, Henry MA, Luo S,
Hargreaves KM: Vanilloids induce oral cancer apoptosis independent of
TRPV1. Oral Oncol 2014 [Epud ahead of print].
doi:10.1186/1744-9081-10-5
Cite this article as: Ye et al.: IB4(+) and TRPV1(+) sensory neurons
mediate pain but not proliferation in a mouse model of squamous cell
carcinoma. Behavioral and Brain Functions 2014 10:5.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
